Joseph Murray
Endocrinology, Diabetes & Metabolism · Metairie, LANPI 1235226101
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,919 and has fallen 54.1% since, to $881 in 2023.
Across 440 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$721
- Abbott$702
- Lilly USA, LLC$608
- Merck$543
- Sanofi-aventis U.S. LLC$321
- plus $3K from 28 others
What the payments were for
- Food & beverage$7,23799%
- Education$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 70 | $1,175 |
| AstraZeneca(2 entities) | 42 | $721 |
| Abbott | 40 | $702 |
| Lilly USA, LLC | 38 | $608 |
| Merck | 37 | $543 |
| Sanofi-aventis U.S. LLC | 19 | $321 |
| Medtronic(2 entities) | 23 | $290 |
| Dexcom, Inc. | 16 | $286 |
| Amgen | 15 | $273 |
| AbbVie | 20 | $264 |
| Johnson & Johnson | 19 | $264 |
| Antares Pharma, Inc. | 11 | $260 |
| Corcept Therapeutics | 12 | $230 |
| Xeris Pharmaceuticals, Inc. | 11 | $212 |
| Boehringer Ingelheim | 11 | $208 |
| Amarin Pharma, Inc. | 8 | $152 |
| Amneal Pharmaceuticals LLC | 9 | $119 |
| IBSA Pharma Inc. | 7 | $113 |
| Bayer | 5 | $92 |
| BD | 4 | $86 |
| Clarus Therapeutics Inc. | 3 | $48 |
| Radius Health, Inc. | 2 | $44 |
| Lifescan, Inc. | 3 | $42 |
| Embecta Corp. | 2 | $35 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Acerus Pharmaceuticals Corporation | 2 | $26 |
| Pfizer | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Rochester Medical Corporation | 1 | $15 |
| GRT US Holding, Inc. | 1 | $15 |
| Mannkind Corporation | 1 | $14 |
| Insulet Corporation | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$125
How this compares
$7,274 in reported general payments places this provider in the 60th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $968 |
| SynthroidLevothyroxine Sodium | 11 | $876 |
| Liothyronine Sodium | 11 | $551 |
| Levothyroxine Sodium | 42 | $473 |
| Metformin Hcl ErMetformin Hcl | 27 | $329 |
| Methimazole | 14 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieSynthroid | $264 | $87611 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $119 | $47342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Metairie
- Julie TalaveraMetairie$49K
- Tuan Huy TranMetairie$34K
- Jonathan WiseMetairie$20K
- Miguel RiveraMetairie$7K
- Escipion PedrozaMetairie$2K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.